Cover Image
Market Research Report

ASIA PACIFIC ANTIFUNGAL AGENTS MARKET FORECAST 2018-2026

Published by Inkwood Research Product code 492771
Published Content info 67 Pages
Delivery time: 2-3 business days
Price
Back to Top
ASIA PACIFIC ANTIFUNGAL AGENTS MARKET FORECAST 2018-2026
Published: August 6, 2018 Content info: 67 Pages
Description

KEY FINDINGS

Asia Pacific antifungal agent market is being driven by factors like poor hygiene in the region, the development of new antifungal drugs and supportive government programs. By the end of the forecast period of 2018-2026, the market is likely to register a CAGR of 5.39%.

MARKET INSIGHTS

The Antifungal agents market is segmented on the basis of type, application, therapeutic indications and drug types. Japan contributed a significant share to this market in 2017, followed by China and India.Initiatives taken by the government of these countries towards healthcare policies and programs are significantly contributing to the growth of the antifungal agents market in the Asia Pacific region. However, alternate treatment options and regulatory conditions could restrain the growth of this market in the coming years.

COMPETITIVE INSIGHTS

Companies like Abbott Laboratories, Vertex Pharmaceuticals, Bayer Healthcare, Johnson & Johnson, Baxter, Astellas Pharma Inc, GlaxoSmithKline, Novartis, Arbor Pharmaceuticals Inc, Kramer Laboratories, Pfizer, Sanofi-Aventis, Gilead and Teva Pharmaceuticals.

Table of Contents
Product Code: 5063

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION
  • 2.5. ESTIMATION METHODOLOGY

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. TROPICAL DRUGS MARKET IS THE EMERGING APPLICATION
    • 3.2.2. ASPERGILLOSIS THERAPEUTIC INDICATION IS LEADING THE MARKET

4. MARKET DETERMINANTS

  • 4.1. MARKET DRIVERS
    • 4.1.1. POOR HYGIENE HABITS
    • 4.1.2. DEVELOPMENT OF DRUG RESISTANCE
    • 4.1.3. HEALTHCARE POLICIES AND PROGRAMS BY GOVERNMENT
  • 4.2. MARKET RESTRAINTS
    • 4.2.1. ALTERNATE TREATMENT OPTIONS
    • 4.2.2. REGULATORY ATMOSPHERE
  • 4.3. MARKET OPPORTUNITIES
    • 4.3.1. EMERGING PIPELINE OF NEW AND INNOVATIVE ANTIFUNGAL DRUGS
    • 4.3.2. HEALTHCARE AND RELATED INDUSTRIES ARE GROWING CONTINUOUSLY
    • 4.3.3. INCREASING AWARENESS AND AVAILABILITY OF INFORMATION
  • 4.4. MARKET CHALLENGES
    • 4.4.1. GROWTH AND DEVELOPMENT OF THE GENERIC ANTIFUNGAL DRUGS MARKET
    • 4.4.2. SIDE EFFECTS AND RECURRING FUNGAL INFECTIONS
    • 4.4.3. RESISTANCE TO DRUGS
    • 4.4.4. RAPIDLY CHANGING TECHNOLOGY

5. MARKET SEGMENTATION

  • 5.1. MARKET BY DRUG TYPES 2018-2026
    • 5.1.1. SYSTEMIC AZOLES
    • 5.1.2. TOPICAL AZOLES
    • 5.1.3. SYSTEMIC POLYENES
    • 5.1.4. TOPICAL POLYENES
    • 5.1.5. SYSTEMIC ECHINOCANDINS
    • 5.1.6. SYSTEMIC ANTIMETABOLICS
    • 5.1.7. OTHER SYSTEMIC
    • 5.1.8. OTHER TOPICAL
    • 5.1.9. OTHER DRUGS TYPES
  • 5.2. MARKET BY THERAPEUTIC INDICATIONS 2018-2026
    • 5.2.1. ASPERGILLOSIS MARKET
    • 5.2.2. DERMATOPHYTOSIS MARKET
    • 5.2.3. CANDIDIASIS MARKET
    • 5.2.4. OTHER THERAPEUTIC INDICATION MARKET
  • 5.3. MARKET BY APPLICATIONS 2018-2026
    • 5.3.1. TOPICAL ANTIFUNGAL AGENTS MARKET
    • 5.3.2. ORAL DRUGS MARKET
  • 5.4. MARKET BY TYPES 2018-2026
    • 5.4.1. PRESCRIPTION
    • 5.4.2. OVER THE COUNTER (OTC)

6. KEY ANALYTICS

  • 6.1. PORTER'S FIVE FORCE MODEL
    • 6.1.1. THREAT OF NEW ENTRANTS
    • 6.1.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
    • 6.1.3. BARGAINING POWER OF BUYER
    • 6.1.4. BARGAINING POWER OF SUPPLIER
    • 6.1.5. INTENSITY OF COMPETITIVE RIVALRY
  • 6.2. KEY BUYING CRITERIA
  • 6.3. VALUE CHAIN ANALYSIS
    • 6.3.1. MANUFACTURERS
    • 6.3.2. DISTRIBUTORS
    • 6.3.3. RETAILERS
    • 6.3.4. END-USERS
  • 6.4. REGULATORY FRAMEWORK
    • 6.4.1. REGULATION IN ASIA PACIFIC
  • 6.5. OPPORTUNITY MATRIX

7. GEOGRAPHICAL ANALYSIS

  • 7.1. ASIA PACIFIC
    • 7.1.1. INDIA
    • 7.1.2. CHINA
    • 7.1.3. JAPAN
    • 7.1.4. SOUTH KOREA
    • 7.1.5. TAIWAN
    • 7.1.6. REST OF APAC

8. COMPANY PROFILES

  • 8.1. COMPETITIVE LANDSCAPE
    • 8.1.1. MARKET SHARE ANALYSIS
  • 8.2. ABBOTT LABORATORIES.
    • 8.2.1. COMPANY OVERVIEW
    • 8.2.2. PRODUCT PORTFOLIO
    • 8.2.3. SCOT ANALYSIS
    • 8.2.4. STRATEGIC INITIATIVES
  • 8.3. ARBOR PHARMACEUTICALS, INC.
    • 8.3.1. COMPANY OVERVIEW
    • 8.3.2. PRODUCT PORTFOLIO
    • 8.3.3. SCOT ANALYSIS
    • 8.3.4. STRATEGIC INITIATIVES
  • 8.4. BAXTER
    • 8.4.1. COMPANY OVERVIEW
    • 8.4.2. PRODUCT PORTFOLIO
    • 8.4.3. SCOT ANALYSIS
    • 8.4.4. STRATEGIC INITIATIVES
  • 8.5. ASTELLAS PHARMA INC.
    • 8.5.1. COMPANY OVERVIEW
    • 8.5.2. PRODUCT PORTFOLIO
    • 8.5.3. SCOT ANALYSIS
    • 8.5.4. STRATEGIC INITIATIVES
  • 8.6. BAYER HEALTHCARE
    • 8.6.1. COMPANY OVERVIEW
    • 8.6.2. PRODUCT PORTFOLIO
    • 8.6.3. SCOT ANALYSIS
    • 8.6.4. STRATEGIC INITIATIVE
  • 8.7. TEVA PHARMACEUTICALS
    • 8.7.1. COMPANY OVERVIEW
    • 8.7.2. PRODUCT PORTFOLIO
    • 8.7.3. SCOT ANALYSIS
    • 8.7.4. STRATEGIC INITIATIVES
  • 8.8. GILEAD
    • 8.8.1. COMPANY OVERVIEW
    • 8.8.2. PRODUCT PORTFOLIO
    • 8.8.3. SCOT ANALYSIS
    • 8.8.4. STRATEGIC INITIATIVES
  • 8.9. GLAXOSMITHKLINE
    • 8.9.1. COMPANY OVERVIEW
    • 8.9.2. PRODUCT PORTFOLIO
    • 8.9.3. SCOT ANALYSIS
    • 8.9.4. STRATEGIC INITIATIVES
  • 8.10. JOHNSON & JOHNSON
    • 8.10.1. COMPANY OVERVIEW
    • 8.10.2. PRODUCT PORTFOLIO
    • 8.10.3. SCOT ANALYSIS
    • 8.10.4. STRATEGIC INITIATIVES
  • 8.11. KRAMER LABORATORIES
    • 8.11.1. COMPANY OVERVIEW
    • 8.11.2. PRODUCT PORTFOLIO
    • 8.11.3. SCOT ANALYSIS
  • 8.12. MERCK & CO.
    • 8.12.1. COMPANY OVERVIEW
    • 8.12.2. PRODUCT PORTFOLIO
    • 8.12.3. SCOT ANALYSIS
    • 8.12.4. STRATEGIC INITIATIVES
  • 8.13. NOVARTIS
    • 8.13.1. COMPANY OVERVIEW
    • 8.13.2. PRODUCT PORTFOLIO
    • 8.13.3. SCOT ANALYSIS
    • 8.13.4. STRATEGIC INITIATIVES
  • 8.14. PFIZER
    • 8.14.1. COMPANY OVERVIEW
    • 8.14.2. PRODUCT PORTFOLIO
    • 8.14.3. SCOT ANALYSIS
    • 8.14.4. STRATEGIC INITIATIVES
  • 8.15. SANOFI-AVENTIS
    • 8.15.1. COMPANY OVERVIEW
    • 8.15.2. PRODUCT PORTFOLIO
    • 8.15.3. SCOT ANALYSIS
    • 8.15.4. STRATEGIC INITIATIVE
  • 8.16. VERTEX PHARMACEUTICALS
    • 8.16.1. COMPANY OVERVIEW
    • 8.16.2. PRODUCT PORTFOLIO
    • 8.16.3. SCOT ANALYSIS
    • 8.16.4. STRATEGIC INITIATIVE

TABLE LIST

  • TABLE 1 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET 2018-2026 ($MILLION)
  • TABLE 2 SKIN LESIONS OCCURRING DUE TO ANTIFUNGAL INFECTION
  • TABLE 3 INDIAN GOVERNMENT INITIATIVES IN HEALTHCARE SECTOR
  • TABLE 4 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET BY DRUG TYPES MARKET 2018-2026 ($ MILLION)
  • TABLE 5 DRUG USES OF TRIAZOLES
  • TABLE 6 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN SYSTEMIC AZOLES 2018-2026 ($ MILLION)
  • TABLE 7 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN TOPICAL AZOLES 2018-2026 ($ MILLION)
  • TABLE 8 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN SYSTEMIC POLYENES 2018-2026 ($ MILLION)
  • TABLE 9 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN TOPICAL POLYENES 2018-2026 ($ MILLION)
  • TABLE 10 INDICATION AND DOSES OF ECHINOCANDIN BY US APPROVED DRUG USAGE
  • TABLE 11 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN SYSTEMIC ECHINOCANDINS 2018-2026 ($ MILLION)
  • TABLE 12 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN SYSTEMIC ANTIMETABOLICS 2018-2026 ($ MILLION)
  • TABLE 13 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN OTHER SYSTEMIC 2018-2026 ($ MILLION)
  • TABLE 14 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN OTHER TOPICAL 2018-2026 ($ MILLION)
  • TABLE 15 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN OTHER DRUGS TYPES MARKET 2018-2026 ($ MILLION)
  • TABLE 16 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET BY THERAPEUTIC INDICATIONS MARKET 2018-2026 ($ MILLION)
  • TABLE 17 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN ASPERGILLOSIS 2018-2026 ($ MILLION)
  • TABLE 18 SYMPTOMS IN THE AFFECTED AREA CAUSED BY DERMATOPHYTES
  • TABLE 19 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN DERMATOPHYTOSIS MARKET 2018-2026 ($ MILLION)
  • TABLE 20 SYMPTOMS IN THE AFFECTED AREA CAUSED BY CANDIDIASIS
  • TABLE 21 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN CANDIDIASIS 2018-2026 ($ MILLION)
  • TABLE 22 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN OTHER THERAPEUTIC INDICATION 2018-2026 ($ MILLION)
  • TABLE 23 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET BY APPLICATIONS MARKET 2018-2026 ($ MILLION)
  • TABLE 24 PROS AND CONS OF TOPICAL MEDICATIONS
  • TABLE 25 ANTIFUNGAL POWDERS AND IT'S EFFECT
  • TABLE 26 ANTIFUNGAL OINTMENT AND IT'S EFFECT
  • TABLE 27 ANTIFUNGAL PASTES AND IT'S EFFECT
  • TABLE 28 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN TOPICAL ANTIFUNGAL AGENTS 2018-2026 ($ MILLION)
  • TABLE 29 COMMONLY USED ANTIFUNGAL DRUGS DOSAGE AND IT'S EFFECTS
  • TABLE 30 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN ORAL DRUGS 2018-2026 ($ MILLION)
  • TABLE 31 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET BY TYPES 2018-2026 ($ MILLION)
  • TABLE 32 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN PRESCRIPTION 2018-2026 ($ MILLION)
  • TABLE 33 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN OTC 2018-2026 ($ MILLION)
  • TABLE 34 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET BY COUNTRIES 2018-2026($ MILLION)
  • TABLE 35 INDIA'S HEALTHCARE SECTOR INVESTMENT
  • TABLE 36 COMPANIES IN CHINA PRODUCING ANTIFUNGAL DRUGS
  • FIGURES LIST
  • FIGURE 1 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET 2018-2026 ($MILLION)
  • FIGURE 2 TOPICAL ANTIFUNGAL AGENTS TYPES
  • FIGURE 3 PORTER'S FIVE FORCE MODEL IN ANTIFUNGAL AGENTS MARKET
  • FIGURE 4 VALUE CHAIN OF ANTIDEPRESSANT DRUGS
  • FIGURE 5 INDIA ANTIFUNGAL AGENTS MARKET 2018-2026($ MILLION)
  • FIGURE 6 CHINA ANTIFUNGAL AGENTS MARKET 2018-2026($ MILLION)
  • FIGURE 7 JAPAN ANTIFUNGAL AGENTS MARKET 2018-2026($ MILLION)
  • FIGURE 8 SOUTH KOREA ANTIFUNGAL AGENTS MARKET 2018-2026($ MILLION)
  • FIGURE 9 TAIWAN ANTIFUNGAL AGENTS MARKET 2018-2026($ MILLION)
  • FIGURE 10 REST OF APAC ANTIFUNGAL AGENTS MARKET 2018-2026($ MILLION)
  • FIGURE 11 ANTI-FUNGAL AGENT COMPANY MARKET SHARE ANALYSIS 2017 (%)
Back to Top